Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

References

• TalpazMShahNP2006Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasN Engl J Med354242531254116775234
   PubMed Web of Science ®Google Scholar
• HochhausABaccaraniMDasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia20082261200120618401416
   PubMed Web of Science ®Google Scholar
• SchifferCABCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemiaN Engl J Med2007357325826517634461
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotF2006Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med355232408241717151364
   PubMed Web of Science ®Google Scholar
• OlivieriAManzioneLDasatinib: a new step in molecular target therapyAnn Oncol200718Suppl 6vi4246
   Google Scholar
• Quintas-CardamaACortesJTherapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemiaClin Cancer Res200814144392439918628453
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaACortesJManagement of patients with resistant or refractory chronic myelogenous leukemiaOncology (Williston Park)20082244307 discussion 437, 442, 446 passim18472616
   PubMed Web of Science ®Google Scholar
• ThomasDAFaderlSTreatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylateBlood2004103124396440714551133
   PubMed Web of Science ®Google Scholar
• DonatoNJWuJYBCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Blood2003101269069812509383
   PubMed Web of Science ®Google Scholar
• PorkkaKKoskenvesaPDasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemiaBlood2008112410051218477770
   PubMed Web of Science ®Google Scholar
• AmreinPCAttarECA phase II study of dasatinib in relapsed and refractory chronic lymphocytic leukemia (CLL/SLL)Blood (ASH Annual Meeting Abstracts)20071103126
   Web of Science ®Google Scholar
• ChiapporiAATanvetyanonTPhase I trial evaluating the epidermal growth factor receptor inhibitor erlotinib in combination with the SRC kinase inhibitor dasatinib for patients with recurrent non-small cell lung cancer (NSCLC)J Clin Oncol200826May 20 suppl abstr 14605
   Google Scholar
• EsteveFRStollerRG2008Phase I trial of cetuximab (C) and dasatinib (D) in patients (pts) with advanced solid malignanciesJ Clin Oncol200826May 20 suppl abstr 14668
   Google Scholar
• KopetzSWolffRAPhase I study of Src inhibition with dasatinib in combination with 5-fluoruracil, leucovorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancerASCO Gastrointestinal Symposium2008Abstract No: 325
   Google Scholar
• YuEYWildingGDasatinib in patients with hormone-refractory progressive prostate cancer: A phase II studyJ Clin Oncol200826May 20 suppl abstr 5156
   Google Scholar
• AguillonRALlanosCADasatinib induces apoptosis in chronic lymphocytic leukemia and enhances the activity of rituximab and fludarabineBlood (ASH Annual Meeting Abstracts)20071101116
   Web of Science ®Google Scholar
• BaumgartnerCGleixnerKVDasatinib inhibits the growth of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRBlood (ASH Annual Meeting Abstracts)20071103559
   Web of Science ®Google Scholar
• RondoniMPaoliniSResponse to dasatinib in patients with aggressive systemic mastocytosis with D816V kit mutationBlood (ASH Annual Meeting Abstracts)20071103562
   Web of Science ®Google Scholar
• WildesTMRuddellAThe activity and toxicity of dasatinib in relapsed or plateau-phase multiple myelomaBlood (ASH Annual Meeting Abstracts)20071101182
   Web of Science ®Google Scholar
• Dasatinib (sprycell) for CML and Ph+ ALLMed Lett Drugs Ther2007491252
   Web of Science ®Google Scholar
• CoplandMHamiltonADasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fractionBlood2006107114532453916469872
   PubMed Web of Science ®Google Scholar
• KantarjianHCML From Bench to ODAC Educational Session2006
   Google Scholar
• HochhausAKantarjianHMDasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood200710962303230917138817
   PubMed Web of Science ®Google Scholar
• MauroMJBaccaraniMDasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)J Clin Oncol200826May 20 suppl abstr 7009
   Google Scholar
• KantarjianHSchifferCMonitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methodsBlood200811141774178018055868
   PubMed Web of Science ®Google Scholar
• GuilhotFApperleyJDasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseBlood2007109104143415017264298
   PubMed Web of Science ®Google Scholar
• GuilhotFApperleyJEfficacy of dasatinib in patients with accelerated phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2 year follow-up data from START-A (CA180-005)Blood (ASH Annual Meeting Abstracts Nov 2007)2008110470
   Google Scholar
• CortesJRousselotPDasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisBlood200710983207321317185463
   PubMed Web of Science ®Google Scholar
• GambacortiCCortesJEfficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START ProgramBlood (ASH Annual Meeting Abstracts)2007110472
   Web of Science ®Google Scholar
• OttmannODombretHDasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyBlood200711072309231517496201
   PubMed Web of Science ®Google Scholar
• FoaRVignettiMDasatinib as front-line monotherapy for the induction treatment of adult and elderly Ph+ acute lymphoblastic leukemia (ALL) patients: interim analysis of the GIMEMA Prospective Study LAL1205Blood (ASH Annual Meeting Abstracts)20071107
   Web of Science ®Google Scholar
• RavandiFThomasDPhase II study of combination of the hyperCVAD regimen with dasatinib in patients with Philadelphia chromosome (Ph) or BCR-ABL positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB)Blood (ASH Annual Meeting Abstracts)20071102814
   Web of Science ®Google Scholar
• StoneRMKantarjianHMEfficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180–013)Blood (ASH Annual Meeting Abstracts)2007110734
   Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHPleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failureJ Clin Oncol200725253908391417761974
   PubMed Web of Science ®Google Scholar
• PunnialingamSde LavalladeHPleural effusions associated with use of dasatinib in chronic myeloid leukemia may have an autoimmune pathogenesisBlood (ASH Annual Meeting Abstracts)20071102945
   Web of Science ®Google Scholar
• MustjokiSLaurinolliTClonal large granular lymphocyte (LGL) expansion associated with dasatinib therapyBlood (ASH Annual Meeting Abstracts)20071102938
   Web of Science ®Google Scholar
• ZamoyskaRBassonAThe influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activationImmunol Rev200319110711812614355
   PubMed Web of Science ®Google Scholar
• ShahNPKantarjianHMIntermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaJ Clin Oncol200826193204321218541900
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov. Advanced chronic myelogenous leukemia (CML) – follow on: study of BMS-354825 in subjects with CML. ClinicalTrials.gov Identifier: NCT00123487.
   Google Scholar
• KantarjianHPasquiniRDasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trialBlood2007109125143515017317857
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSOutcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failureCancer200710981556156017342766
   PubMed Web of Science ®Google Scholar
• KantarjianHGilesFNilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLN Engl J Med2006354242542255116775235
   PubMed Web of Science ®Google Scholar
• KantarjianHHochhausANilotinib Is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intoleranceBlood (ASH Annual Meeting Abstracts)2007110735
   PubMed Web of Science ®Google Scholar
• Le CoutrePGilesFJNilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intoleranceBlood (ASH Annual Meeting Abstracts)2007110471
   Web of Science ®Google Scholar
• GilesFJLarsonRANilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinibBlood (ASH Annual Meeting Abstracts)20071101025
   PubMed Web of Science ®Google Scholar
• CangSLiuDP-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemiaJ Hematol Oncol200811518828913
   PubMed Web of Science ®Google Scholar
• HochhausAErbenPResistance to targeted therapy in chronic myelogenous leukemiaSemin Hematol2007441 Suppl 1S15S2417292737
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov. Compare bosutinib to imatinib in subjects with newly diagnosed chronic phase Philadelphia chromosome positive CML. ClinicalTrials.gov Identifier: NCT00574873.
   Google Scholar
• www.clinicaltrials.gov. A phase III study of dasatinib vs. imatinib in patients with newly diagnosed chronic phase CML. ClinicalTrials.gov Identifier: NCT00481247.
   Google Scholar
• www.clinicaltrials.gov. Study of dasatinib in patients with chronic myelogenous leukemia. ClinicalTrials.gov Identifier: NCT00254423.
   Google Scholar
• CortesJO’BrienSEfficacy of nilotinib (AMN107) in patients (pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP)Blood (ASH Annual Meeting Abstracts)200711029
   PubMed Web of Science ®Google Scholar
• CortesJO’BrienSEfficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)Blood (ASH Annual Meeting Abstracts)200711030
   Web of Science ®Google Scholar
• www.clinicaltrials.gov. A study of imatinib versus nilotinib in adult patients with newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukemia in chronic phase (CML_CP) (ENEST) ClinicalTrials.gov Identifier: NCT00471497.
   Google Scholar
• www.clinicaltrials.gov. A phase III study of dasatinib vs imatinib in patients with newly diagnosed chronic phase CML. ClinicalTrials.gov Identifier: NCT00481247, C. g. I.
   Google Scholar
• www.clinicaltrials.gov. A study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) (ENEST). ClinicalTrials.gov Identifier: NCT00471497.
   Google Scholar